Abstract

Background

Metformin is frequently prescribed for polycystic ovary syndrome (PCOS). There is a well-established causal relationship between metformin use in type 2 diabetes and vitamin B12 deficiency; such a relationship is seldom studied in PCOS. We conducted this study to compare vitamin B12 levels among newly diagnosed and metformin-treated patients with PCOS.

Methodology

This cross-sectional comparative study was conducted from July 2021 to June 2022, among patients with PCOS attending a specialized endocrinology clinic of a tertiary hospital in Mymensingh, Bangladesh. A total of 50 patients newly diagnosed with PCOS and 52 with PCOS who had received metformin for at least six months were evaluated. The serum vitamin B12 level was measured by utilizing the chemiluminescent microparticle immunoassay principle.

Results

The new drug-naïve and metformin-treated subjects with PCOS had similar clinical and laboratory parameters except for the metformin group’s lower hemoglobin levels and higher plateletcrit. Metformin receivers had lower serum vitamin B12 levels than the drug-naïve subjects (385.5 pg/mL [interquartile range, or IQR, 298.7-535.2] vs. 272.0 pg/mL [IQR 217.0-395.7]; \( P < 0.001 \)). The metformin group had higher frequencies of B12 deficiency and borderline deficiency (15.4% vs. 6% and 42.3% vs. 18%, respectively; \( P = 0.003 \)).

Conclusions

This study observed lower serum B12 levels in PCOS patients using metformin than in the newly diagnosed ones. Large-scale data are needed to recommend routine periodic screening for B12 levels in metformin-treated PCOS.
adverse hematological, neuropsychiatric, and cardiovascular consequences [10]. Although data regarding B12 deficiency in metformin-treated patients with type 2 diabetes mellitus (T2DM) are widely available in the literature, similar evidence in PCOS is scarce [10,11]. With this background, we conducted this study to compare vitamin B12 levels among newly diagnosed and metformin-treated patients with PCOS.

Materials And Methods

This cross-sectional comparative study was conducted from July 2021 to June 2022 among patients with PCOS attending a specialized endocrinology clinic of a tertiary hospital in Mymensingh, Bangladesh. A total of 50 patients newly diagnosed with PCOS and 52 with PCOS who had received metformin for at least six months were evaluated. PCOS was diagnosed using the revised Rotterdam criteria for adults [12]. In adolescent girls, PCOS diagnosis was made based on clinical and/or biochemical hyperandrogenism (after the exclusion of other causes) in the presence of persistent menstrual irregularities [13]. Patients having any comorbid conditions that may interfere with the vitamin B12 level (e.g., pernicious anemia, malabsorption, and gastrointestinal surgery), those with thyroid disorders and advanced hepatic and renal disease, those with chronic (three months or more) use of acid suppressants (i.e., proton pump inhibitors or H2 receptor blockers) and chronic alcohol abuse, and those who are vegetarians, getting supplementation of B12 or any B12 containing multivitamin, and using drugs that affect B12 levels (e.g., corticosteroids, phenytoin, and dihydrofolate reductase inhibitors) were excluded. Informed written consent was taken from the study subjects. The study was conducted according to Good Clinical Practice and the Declaration of Helsinki.

A convenient sampling technique was followed to collect samples. The study subjects were divided into two groups: those with ongoing treatment with metformin for at least six months were included in the metformin group, and those newly diagnosed with PCOS and who never received metformin in their lifetime were included in the non-metformin group. A semistructured questionnaire-based interview was conducted to collect relevant demographic and clinical information. Random venous blood samples were collected, and complete blood count (CBC) and serum vitamin B12 levels were assessed on the same day of blood sample collection. Using the Fluorescence Flow Cytometry method, the CBC was estimated by the hematology autoanalyzer Sysmex XN-2000 (Sysmex, Kobe, Japan). The serum vitamin B12 level was measured by an automated immunoassay analyzer Alinity I System (Abbott Laboratories, Abbott Park, IL, USA) utilizing the chemiluminescent microparticle immunoassay (CMIA) principle. The serum vitamin B12 level ≤200 pg/mL was labeled as a deficiency, >200 to ≤300 pg/mL as a borderline deficiency, and >300 pg/mL was labeled as normal [14].

Data were analyzed using the IBM SPSS Statistics for Macintosh software (Version 28.0; IBM Corp. Released 2021, Armonk, NY, USA). The continuous variables with and without a normal distribution were expressed as mean ± standard deviation and median (interquartile range [IQR]), respectively. The categorical variables were presented as the percentage (number). As applicable, the Student’s t-test, the Chi-square test, and the Mann-Whitney U test were applied to compare the variables between the two groups. A two-sided P-value of less than 0.05 indicates statistical significance.

Results

A total of 50 drug-naïve women newly diagnosed with PCOS and 52 women previously diagnosed with PCOS and on metformin were evaluated; the sample size gave 98.7% power to the study. In the metformin group, the median duration of metformin use was 13.5 (IQR 7.0-23.5) months and the median metformin dose was 1.0 (IQR 0.78-1.0) g.

Women in the two groups had similar age; BMI; systolic and diastolic blood pressure (BP) readings; fasting plasma glucose (FPG); WBC; neutrophil, lymphocyte, monocyte, eosinophil, and red blood cell (RBC) counts; mean corpuscular volume (MCV); mean corpuscular hemoglobin (MCH); MCH concentration (MCHC); red cell distribution width-coefficient of variation (RDW-CV); mean platelet volume (MPV); platelet distribution width (PDW); and erythrocyte sedimentation rate (ESR). The metformin group had lower hemoglobin levels and higher plateletcrit (PCT) than drug-naive subjects (Table 1).
### TABLE 1: Comparison of clinical and laboratory parameters of new drug-naïve and metformin-treated subjects with PCOS.

| Variables          | Drug-naive (n = 50) | Metformin-treated (n = 52) | P-value |
|--------------------|---------------------|---------------------------|---------|
| Age (years)        | 21.0 (18.7-25.0)    | 22.5 (19.0-26.0)          | 0.221   |
| BMI (kg/m²)        | 26.38 (23.41-29.12) | 25.13 (22.77-27.26)       | 0.123   |
| Systolic BP (mmHg) | 125 (115-130)       | 120 (110-130)             | 0.442   |
| Diastolic BP (mmHg)| 80 (75-80)          | 80 (71-80)                | 0.910   |
| FPG (mmol/L)       | 4.9 (4.6-5.4)       | 4.8 (4.5-5.2)             | 0.542   |
| WBC (K/mL)         | 9.24 ± 2.38         | 9.61 ± 2.07               | 0.411   |
| Neutrophil (K/mL)  | 5.46 ± 1.77         | 5.48 ± 1.63               | 0.944   |
| Lymphocyte (K/mL)  | 3.12 ± 1.02         | 3.40 ± 0.86               | 0.132   |
| Monocyte (K/mL)    | 0.36 (0.29-0.47)    | 0.35 (0.30-0.44)          | 0.920   |
| Eosinophil (K/mL)  | 0.23 (0.13-0.36)    | 0.28 (0.17-0.42)          | 0.149   |
| RBC (K/mL)         | 4.84 (4.36-5.11)    | 4.62 (4.30-4.84)          | 0.079   |
| Hemoglobin (g/dL)  | 12.85 (12.0-13.52)  | 12.45 (11.45-13.18)       | 0.048   |
| Hematocrit (%)     | 38.95 (36.07-41.42) | 38.3 (35.5-40.3)          | 0.158   |
| MCV (fL)           | 82.2 (77.3-87.8)    | 83.1 (77.9-86.7)          | 0.883   |
| MCH (pg)           | 27.4 (25.9-29.1)    | 27.6 (25.3-28.9)          | 0.673   |
| MCHC (g/dL)        | 32.9 (32.1-34.2)    | 32.5 (32.0-33.3)          | 0.115   |
| RDW-CV (%)         | 13.1 (12.6-13.9)    | 13.2 (12.5-14.3)          | 0.653   |
| Platelet (K/mL)    | 306.5 (262.7-354.7) | 325.5 (291.0-381.5)       | 0.074   |
| MPV (fL)           | 10.3 (9.8-11.0)     | 10.3 (9.8-11.3)           | 0.889   |
| PCT (%)            | 0.33 ± 0.06         | 0.345 ± 0.06              | 0.031   |
| PDW (fL)           | 12.8 (11.1-14.8)    | 12.0 (10.5-14.2)          | 0.236   |
| ESR (mm in the first hour) | 25.0 (13.2-33.2) | 25.0 (17.0-35.7)          | 0.357   |

Metformin receivers had lower serum vitamin B12 levels than the drug-naïve group [385.5 (IQR 298.7-535.2) pg/mL vs. 272.0 pg/mL (IQR 217.0-395.7), P < 0.001] (Figure 1).
FIGURE 1: Comparison of vitamin B12 levels among drug-naïve and metformin-treated subjects with PCOS.

PCOS, polycystic ovary syndrome

The frequency of B12 deficiency and borderline deficiency was higher in the metformin group ($P = 0.003$; Figure 2).

FIGURE 2: Comparison of vitamin B12 status among drug-naïve and metformin-treated subjects with PCOS.

PCOS, polycystic ovary syndrome

Discussion

This study investigates the vitamin B12 status in metformin-treated patients with PCOS and compares their B12 levels with those of newly diagnosed, drug-naïve patients with PCOS. We observed that metformin receivers had lower serum vitamin B12 levels than the drug-naïve group and that the frequency of B12 deficiency and borderline deficiency was higher in the metformin group. Metformin receivers also had lower hemoglobin levels than the drug-naïve group.
Vitamin B12, or cobalamin, is a vital nutrient for health that plays an essential role in the functioning of the nervous system and the formation of RBCs. In addition to anemia, B12 deficiency may lead to peripheral neuropathy and dementia [15]. Furthermore, B12 participates in the homocysteine metabolism pathway, and B12 deficiency leads to hyperhomocysteinemia, which is strongly linked to cardiovascular disease [16]. Metformin is a commonly prescribed drug for PCOS. Generally, metformin is well tolerated except for gastrointestinal intolerance in some patients. Metformin use, especially in the long term, is associated with vitamin B12 deficiency [17]. Competitive inhibition or inactivation of B12 absorption; alterations in intrinsic factor levels; gut bacterial flora; gastrointestinal motility, or ileal morphological structure; interaction with the cubulin-endocytic receptor; and impairment of calcium–dependent membrane activity in the ileum, including uptake of the B12–intrinsic factor complex, are the postulated mechanisms of metformin-induced B12 deficiency [11]. Moreover, in one study, serum vitamin B12 concentrations were significantly lower in obese PCOS women compared to obese control women (227.8 ± 99.2 vs. 317.6 ± 69.2; P < 0.05); such baseline deficit may amplify the risk of B12 depletion in these patients when they are treated with metformin [18].

Metformin-associated B12 deficiency in T2DM was first described in 1969, and since then, many researchers have confirmed the dose-dependent lowering of B12 levels with metformin [10, 11, 19]. Only a few studies have evaluated the changes in vitamin B12 in metformin-treated patients with PCOS, and there is great heterogeneity among the study results. Kilıçdag et al. observed a nonsignificant reduction of vitamin B12 after treatment with 1.7 g daily metformin for three months (281.83 ± 24.51 to 226.08 ± 35.42 pg/mL; P = NS) [20]. In another study, Kilıçdag et al. explored a nonsignificant increase in B12 (288.68 ± 24.10 to 328.56 ± 156.81 pg/mL; P = NS) after 1.7 g daily metformin for three months [21]. In lean patients with PCOS, 1.7 g daily metformin for 12 weeks was associated with a nonsignificant reduction in vitamin B12 levels (311.19 ± 71.74 to 309.23 ± 71.12 pg/mL; P = NS) in a study by Yılmaz et al. [22]. On the contrary, Esmaeilzadeh et al. found a significant decrease in the mean B12 level in patients after six months of metformin 1 g/day treatment (456.88 ± 172.32 to 367.69 ± 28.10 pg/mL; P = 0.002) [23]. In a meta-analysis, including these four studies, Li et al. showed no significant change in vitamin B12 levels before and after metformin treatment (mean difference 24.70 pg/mL; 95% confidence interval [CI] –22.54 to 71.93; P = 0.31; moderate heterogeneity [I² = 74%]) [24]. Treatment with metformin was followed by a decline in B12 levels in studies by Greibe et al. (1.5–2.5 g/day for six months) and Khalil et al. (1.5 g/day for 16 weeks) [25, 26]. Palmoba et al. observed no significant reduction in B12 levels (379.3 ± 108.1 to 364.7 ± 123.4; P = NS) in PCOS patients treated with 1.7 g daily metformin for six months [27]. We found that 24% of the newly diagnosed women with PCOS have subnormal B12 levels, which supports Kaya et al.’s finding of lower B12 levels in PCOS than in healthy controls [18]. Though we did not observe the temporal changes in B12 levels in our study subjects, comparison with a control group with similar characteristics justifies our findings of lower B12 levels in metformin users.

The available evidence on changes in B12 levels with metformin in PCOS is inconclusive. Moreover, despite a reduction in total B12 levels with metformin, a study reported no reduction in the active physiological part of cobalamin bound to transcobalamin (holotranscobalamin) or increase in the metabolic marker of cobalamin status, methylmalonic acid. Instead, the nonfunctional part of circulating cobalamin bound to haptocorrin declined [25]. Due to unavailability, we could not assess holotranscobalamin and methylmalonic acid in our study subjects.

This study has many limitations. It was a single-center study with a small sample size questioning the generalizability of the study result. Due to the cross-sectional design and lack of a healthy control group, the causality assessment for B12 deficiency with metformin was beyond our scope. Measurement of holotranscobalamin and methylmalonic acid would strengthen our findings. As we did not assess folic acid and homocysteine levels, the effect of B12 reductions could not be evaluated. Nevertheless, this was the first report of metformin-related B12 deficiency from this region.

Conclusions
This study observed that metformin-treated patients with PCOS have lower serum vitamin B12 levels than newly diagnosed, drug-naïve ones. One-fourth of the new cases of PCOS have subnormal B12 levels; the frequency is 57.7% in metformin receivers. Further large-scale data are needed to recommend routine periodic screening for B12 levels in PCOS.

Additional Information
Disclosures
Human subjects: Consent was obtained or waived by all participants in this study. Mymensingh Medical College issued approval MMC/IRB/2021/236, Date: 23/05/2021. Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could
appear to have influenced the submitted work.

References

1. Skiba MA, Islam RM, Bell RJ, Davis SR: Understanding variation in prevalence estimates of polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update. 2018, 24:694-709. 10.1093/humupd/dmy022

2. Rosenfield RL, Ehrmann DA: The pathogenesis of polycystic ovary syndrome (PCOS): the hypothesis of PCOS as functional ovarian hyperandrogenism revisited. Endocr Rev. 2016, 37:467-520. 10.1210/er.2015-1104

3. Diamanti-Kandarakis E, Dunaf A: Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. Endocr Rev. 2012, 33:981-1030. 10.1210/er.2011-1104

4. Rojas I, Chávez M, Olivar L, et al.: Polycystic ovary syndrome, insulin 2 resistance, and obesity: navigating the pathophysiologic labyrinth. Int J Reprod Med. 2014, 2014:719050. 10.1155/2014/719050

5. Moran LJ, Misso ML, Wild RA, Norman RJ: Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update. 2010, 16:547-63. 10.1093/humupd/dmq01

6. Kamrul-Hasan ABM, Aalpona FTZ: Comparison of clinical, metabolic, and hormonal parameters in lean vs. obese women with polycystic ovary syndrome: a single-center study from Bangladesh. Sri Lanka J Diabetes Endocrinol Metab. 2021, 11:15-25. 10.4058/sjdem.v11i.1.7411

7. Notaro AL, Neto FT: The use of metformin in women with polycystic ovary syndrome: an updated review. J Assist Reprod Genet. 2022, 39:575-9. 10.1007/s10811-022-02429-9

8. Teede HJ, Misso ML, Costello MF, et al.: Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Hum Reprod. 2018, 35:1602-18. 10.1093/humrep/dey256

9. Goodman NF, Cobin RH, Futterweit W, Glueck JS, Legro RS, Carmina E: American Association of Clinical Endocrinologists, American College of Endocrinology, and Androgen Excess and PCOS Society Disease State Clinical Review: guide to the best practices in the evaluation and treatment of polycystic ovary syndrome - part 2. Endocr Pract. 2015, 21:1415-26. 10.4365/ep.2015.21.1415

10. Liu Q, Li S, Quan H, Li J: Vitamin B12 status in metformin treated patients: systematic review. PLoS One. 2014, 9:e100379. 10.1371/journal.pone.0100379

11. Infante M, Leoni M, Caprio M, Fabbri A: Long-term metformin therapy and vitamin B12 deficiency: an association to bear in mind. World J Diabetes. 2021, 12:916-31. 10.4239/wjd.v12i7.916

12. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group: Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004, 81:19-25. 10.1016/j.fertnstert.2003.10.004

13. Legro RS, Arslanian SA, Ehrmann DA, Hoeger KM, Marder MH, Pasquali R, Welt CK: Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2015, 98:4565-92. 10.1210/jc.2015-2550

14. Aroda VR, Edelstein SL, Goldberg RB, et al.: Long-term metformin use and vitamin B12 deficiency in the Diabetes Prevention Program Outcomes Study. J Clin Endocrinol Metab. 2016, 101:1754-61. 10.1210/jc.2015-3754

15. Wolfensbutter BHR, Wouters HJCM, Heiner-Fokkema MR, van der Klauw MM: The many faces of cobalamin (vitamin B12) deficiency. Mayo Clin Proc Innov Qual Outcomes. 2019, 5:200-14. 10.1016/j.mayocpiqo.2019.05.002

16. Ganjy P, Alam SF: Role of homocysteine in the development of cardiovascular disease. Nutr J. 2015, 14:6. 10.1186/1475-2891-14-6

17. Fraison E, Kostova E, Moran LJ, Bilal S, Ee CC, Venetis C, Costello MF: Metformin versus the combined oral contraceptive pill for hirsutism, acne, and menstrual pattern in polycystic ovary syndrome. Cochrane Database Syst Rev. 2020, 8:CD005552. 10.1002/14651858.CD005552.pub3

18. Kaya C, Cericd SD, Saoirogu H: Obesity and insulin resistance associated with lower plasma vitamin B12 in PCOS. Reprod Biomed Online. 2009, 19:721-6. 10.1615/fjrbm.v19.i5.005

19. Kamrul-Hasan AB, Alam MS, Chanda PK, Selim S: Serum vitamin B12 levels in patients with type 2 diabetes mellitus on metformin compared to those never on metformin: a cross-sectional study from Bangladesh. Myrnensingh Med J. 2021, 30:915-20.

20. Kiliçdag EB, Bagis T, Tarim E, et al.: Administration of B-group vitamins reduces circulating homocysteine in polycystic ovarian syndrome patients treated with metformin: a randomized trial. Hum Reprod. 2005, 20:1521-8. 10.1093/humrep/deh256

21. Kiliçdag EB, Bagis T, Zeyneloglu HB, Tarim E, Aslan E, Haydardeoglu B, Erkanli S: Homocysteine levels in women with polycystic ovary syndrome treated with metformin versus rosiglitazone: a randomized study. Hum Reprod. 2005, 20:894-9. 10.1093/humrep/deh700

22. Yildiz M, Bukan N, Ayaz G, Karakoç A, Türüner F, Cakir N, Arslan M: The effects of rosiglitazone and metformin on oxidative stress and homocysteine levels in lean patients with polycystic ovary syndrome. Hum Reprod. 2005, 20:3333-40. 10.1093/humrep/dei258

23. Esmaeizadeh S, Gholinezhad-Chari M, Ghadimi R: The Effect of Metformin Treatment on the Serum Levels of Homocysteine, Folic Acid, and Vitamin B12 in Patients with Polycystic Ovary Syndrome. J Hum Reprod Sci. 2017, 10:95-101. 10.4103/jhrs.JHRS_74_16

24. Li X, Fang Z, Yang X, et al.: The effect of metformin on homocysteine levels in patients with polycystic ovary syndrome: A systematic review and meta-analysis. J Obstet Gynaecol Res. 2021, 47:1804-16. 10.1111/jog.14725

25. Greibe E, Troille B, Bor MV, Laussus FF, Nexo E: Metformin lowers serum cobalamin without changing other markers of cobalamin status: a study on women with polycystic ovary syndrome. Nutrients. 2015, 5:2475-82. 10.3390/nu5072475

26. Khalil IAM: The effect of vitamin B and folic acid supplementation on plasma homocysteine levels in women
with polycystic ovary syndrome treated with metformin: a randomized controlled trial. Austin J Reprod Med Infertil. 2015; 2:1013.

27. Palomba S, Falbo A, Giallauria F, et al.: Effects of metformin with or without supplementation with folate on homocysteine levels and vascular endothelium of women with polycystic ovary syndrome. Diabetes Care. 2010, 33:246-51. 10.2337/dc09-1516.